A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

PHASE4CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Type 2 DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

Tirzepatide

Administered SC

Trial Locations (32)

20852

Endocrine and Metabolic Consultants, Rockville

29607

Mountain View Clinical Research, Inc., Greenville

30076

Endocrine Research Solutions, Inc., Roswell

32204

East Coast Institute for Research, LLC, Jacksonville

32825

Florida Institute For Clinical Research, LLC, Orlando

33009

Velocity Clinical Research, Hallandale Beach, Hallandale

46383

Velocity Clinical Research, Valparaiso, Valparaiso

50265

Iowa Diabetes and Endocrinology Research Center, West Des Moines

63005

Clinical Research Professionals, Chesterfield

66606

Cotton O'Neil Clinic, Topeka

73013

Conrad Clinical Research, Edmond

75165

ClinPoint Trials, Waxahachie

75231

North Texas Endocrine Center, Dallas

78231

Consano Clinical Research, LLC, Shavano Park

85283

Fiel Family and Sports Medicine PC, Tempe

89121

Clinical Research of South Nevada, Las Vegas

89128

Palm Research Center Tenaya, Las Vegas

90057

Velocity Clinical Research, Huntington Park, Los Angeles

90247

Velocity Clinical Research, Gardena, Gardena

90255

Velocity Clinical Research, Huntington Park, Huntington Park

91325

Valley Clinical Trials, Inc., Northridge

91767

Dream Team Clinical Research, Pomona

92882

New Hope Research Development, Corona

92121-1520

Scripps Whittier Diabetes Institute, San Diego

91356-3551

Metabolic Institute of America, Tarzana

06708

CMR of Greater New Haven, LLC, Waterbury

33603-3402

New Tampa Health, Tampa

30044-5896

Georgia Clinical Research, Lawrenceville

40383-1947

Versailles Family Medicine, Versailles

43537-9402

Advanced Medical Research, Maumee

78731-4309

Texas Diabetes & Endocrinology, P.A., Austin

77043-2742

Memorial City Endocrine Consultants, Houston

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY